Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Robert T. Maguire"'
Autor:
Robert A. Volkmann, Johanna Marie Csengery, Vishwas M. Paralkar, Patricia Bourassa, Ranjit S. Bindra, Lori Lopresti-Morrow, Kelli Jones, Sophia Gayle, Qing Zhang, Robert T. Maguire, Robert J. Aiello, Timothy Joseph Paradis, Ketaki Deshpande, Jane Bechtold, Hunter Moore, Peter M. Glazer, Daniel Richard Marshall, Laurie Tylaska
Publikováno v:
Cancer Research. 80:6242-6242
Maytansines and their derived maytansinoid DMx compounds are high potency microtubule targeting compounds that have an extremely narrow therapeutic window. Unacceptable dose limiting systemic toxicity has limited the therapeutic potential of these po
Autor:
Sophia Gayle, Hunter Moore, Patricia Bourassa, Lori Lopresti-Morrow, Robert A. Volkmann, Vishwas M. Paralkar, Peter M. Glazer, Robert J. Aiello, Robert T. Maguire, Timothy Joseph Paradis, Ranjit S. Bindra, Jane Bechtold, Qing Zhang, Kelli Jones, Johanna Marie Csengery, Daniel Richard Marshall, Laurie Tylaska, Ketaki Deshpande
Publikováno v:
Cancer Research. 80:6249-6249
Topoisomerase inhibitors are potent DNA damaging agents with great potential as anti-cancer drugs for a wide range of solid tumors. However, dose-limiting toxicities such as myelosuppression and gastric toxicity have prevented them from reaching thei
Autor:
George L. Wright, Steven Piantadosi, John K. Burgers, John H. Texter, Alan W. Partin, John O. Olsen, John A. Libertino, Michael J. Manyak, George H. Hinkle, Robert T. Maguire, Charles E. Neal, Richard P. Chiaccherini
Publikováno v:
Urology. 54:1058-1063
Objectives. No standard noninvasive diagnostic test reliably differentiates patients with organ-confined prostate cancer from those with lymph node metastases. The ability of a radiolabeled monoclonal antibody, indium-111 ( 111 In)-capromab pendetide
Autor:
Robert T. Maguire, Barbara Rogers, Michael K. Haseman, Thomas J. Polascik, Alan W. Partin, Michael J. Manyak, Robin Gurganus
Publikováno v:
Cancer. 85:1586-1592
BACKGROUND The pretherapy prediction of occult lymph node involvement and the avoidance of otherwise futile and potentially morbid definitive local therapy is paramount in men with newly diagnosed prostate carcinoma. To identify patients with prostat
Autor:
Robert T. Maguire, Jack Gerstbrein, Sara J. Miller, James D. Austin, Richard D. Williams, Daniel Kahn
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 14:99-111
There is currently no curative therapy for men who have disseminated prostate cancer following failed radical prostatectomy. The purpose of this trial was to investigate systemic radioimmunotherapy in these men. Eight patients with occult metastatic
Autor:
Richard D. Williams, Robert T. Maguire, Daniel Kahn, John A. Libertino, Michael K. Haseman, Michael J. Manyak, David W. Seldin
Publikováno v:
Journal of Urology. 159:2041-2047
Purpose: Standard diagnostic methods are limited for detecting distant metastases in patients with prostate cancer in whom the only evidence of disease after radical prostatectomy is a detectable prostate specific antigen (PSA) level. We evaluated th
Autor:
DANIEL KAHN, RICHARD D. WILLIAMS, MICHAEL J. MANYAK, MICHAEL K. HASEMAN, DAVID W. SELDIN, JOHN A. LIBERTINO, ROBERT T. MAGUIRE
Publikováno v:
The Journal of Urology. :2041-2046
Autor:
Barbara Rogers, G.M. Kenny, Alkibiades K. Gregorakis, V.A. Bowes, Eric H. Holmes, Gerald P. Murphy, Alton L. Boynton, Robert T. Maguire, Haakon Ragde, M.J. Troychak, Robert J. Barren, Wil B. Nelp, Alan W. Partin
Publikováno v:
The Prostate. 33:281-285
BACKGROUND Stored serum from clinical trial cases undergoing ProstaScint® (CYT-356) scanning were available for Prostate Specific Membrane Antigen (PSMA) assay. Prostate Specific Antigen (PSA) levels had already been determined. This provided an opp
Autor:
Robert T. Maguire, Hani Abdel-Nabi, George E. Block, George J. Weiner, Susan Galandiuk, Marvin L. Corman, Edith P. Mitchell, Allan N. Maroli, Elliot D. Prager, Daniel Kahn, Virginia L. Pascucci
Publikováno v:
Diseases of the Colon & Rectum. 37:129-137
PURPOSE: The role of immunoscintigraphy with111 Insatumomab pendetide in the medical and/or surgical management of colorectal cancer patients was evaluated in a multicenter trial. METHODS: This 103 patient study population included 46 individuals wit
Publikováno v:
Cancer. 72:3453-3462
Application of monoclonal antibody (MoAb) technology to cancer management is discussed by reviewing the development and clinical evaluation of two MoAb-based immunoscintigraphic agents (111In-satumomab pendetide [OncoScint CR/OV-In] and 111In-CYT-356